Drug developer PDL BioPharma Inc., partly responsible for one of Connecticut’s biggest-selling drug discoveries, said Monday it has agreed to settle a legal dispute with Swiss drug maker Novartis.
PDL BioPharma holds a patent covering one of the key biotechnologies in the Soliris rare blood-disorder treatment that Cheshire drug maker Alexion Pharmaceuticals markets worldwide.
A similar dispute settled two years ago between PDL and Alexion resulted in a $25 million license payment to PDL and a 4 percent royalty payment on Alexion’s future sales of drugs using biotechnology covered under PDL’s Queen patent.
In the Novartis dispute, it is PDL who agreed to pay  Novartis an amount based on the net sales of the eye drug Lucentis made by Novartis this year and beyond.
The settlement resolves all disputes between the companies, PDL said in a statement.
PDL, which is based in Incline Village, Nev., agreed to dismiss claims against Novartis in state court in Nevada, and said Novartis agreed to withdraw its challenge in the European Patent Office of PDL’s Queen patent.
PDL said the settlement does not affect its claims against Genentech Inc. and Roche Ltd. in Nevada court.
